

HR 5675

Liver Illness Visibility, Education, and Research Act of 2021

Congress: 117 (2021–2023, Ended)

Chamber: House

Policy Area: Health

Introduced: Oct 21, 2021

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Oct 22, 2021)

Official Text: <https://www.congress.gov/bill/117th-congress/house-bill/5675>

Sponsor

Name: Rep. Velazquez, Nydia M. [D-NY-7]

Party: Democratic • **State:** NY • **Chamber:** House

Cosponsors (3 total)

Cosponsor	Party / State	Role	Date Joined
Del. Norton, Eleanor Holmes [D-DC-At Large]	D · DC		Oct 21, 2021
Rep. Espaillat, Adriano [D-NY-13]	D · NY		Oct 21, 2021
Rep. Fitzpatrick, Brian K. [R-PA-1]	R · PA		Oct 21, 2021

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 22, 2021

Subjects & Policy Tags

Policy Area:

Health

Related Bills

Bill	Relationship	Last Action
117 S 3041	Related bill	Oct 21, 2021: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Liver Illness Visibility, Education, and Research Act of 2021

This bill expands and coordinates activities related to the research of liver cancer and liver disease, including causes, prevention, detection, and treatment.

Specifically, the National Cancer Institute must establish a working group to coordinate efforts across the National Institutes of Health to cure liver cancer and liver disease, including research into such cases resulting from hepatitis B. The institute may also award grants for developing preventative and diagnostic measures and supporting experimental treatment options.

The bill further establishes grant programs, administered by the Centers for Disease Control and Prevention, to support liver disease prevention services, diagnostics, and hepatitis tracking programs and to raise awareness about liver disease within high-risk communities.

The renamed National Institute of Diabetes and Digestive, Kidney, and Liver Diseases also must prioritize programs addressing liver disease, including (1) establishing a national clearinghouse for patient data, and (2) developing or expanding the centers for research of liver disease.

Actions Timeline

- **Oct 22, 2021:** Referred to the Subcommittee on Health.
- **Oct 21, 2021:** Introduced in House
- **Oct 21, 2021:** Referred to the House Committee on Energy and Commerce.